Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda in metastatic colorectal cancer
NCT02567331Phase 4Completed
- Sponsor
- Roche
- Start
- Oct 2004
- Primary completion
- Apr 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of capecitabine in metastatic colorectal cancer (mCRC), sponsored by Roche. Started Oct 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02567331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567331.